These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21370501)

  • 21. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
    Kim M; Ku JH; Kwak C; Kim HH; Lee E; Keam B; Kim TM; Heo DS; Lee SH; Moon KC
    PLoS One; 2015; 10(7):e0133371. PubMed ID: 26200905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
    Heo SJ; Jung I; Lee CK; Kim JH; Lim SM; Moon YW; Shim HS; Jeong J; Kim JH; Kim HR; Cho BC
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):539-48. PubMed ID: 26811178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report.
    Zeng C; Fan W; Zhang X
    Cell Oncol (Dordr); 2015 Aug; 38(4):319-25. PubMed ID: 26092210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
    Kim SO; Jeong JY; Kim MR; Cho HJ; Ju JY; Kwon YS; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC
    Clin Cancer Res; 2008 May; 14(10):3083-8. PubMed ID: 18483375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
    Mlak R; Krawczyk P; Ramlau R; Kalinka-Warzocha E; Wasylecka-Morawiec M; Wojas-Krawczyk K; Kucharczyk T; Homa I; KozioĊ‚ P; Ciesielka M; Chudziak D; Milanowski J
    Oncol Rep; 2013 Nov; 30(5):2385-98. PubMed ID: 23982437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
    Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
    Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis.
    Gong W; Zhang X; Wu J; Chen L; Li L; Sun J; Lv Y; Wei X; Du Y; Jin H; Dong J
    Lung Cancer; 2012 Mar; 75(3):374-80. PubMed ID: 21889227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
    Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
    Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
    Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
    Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
    Bepler G; Williams C; Schell MJ; Chen W; Zheng Z; Simon G; Gadgeel S; Zhao X; Schreiber F; Brahmer J; Chiappori A; Tanvetyanon T; Pinder-Schenck M; Gray J; Haura E; Antonia S; Fischer JR
    J Clin Oncol; 2013 Jul; 31(19):2404-12. PubMed ID: 23690416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.
    Xu XL; Zhang YP; Fang Y; Su D; Chen W; Feng JG; Li ZP; Mao WM
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C49-55. PubMed ID: 26323924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
    Reynolds C; Obasaju C; Schell MJ; Li X; Zheng Z; Boulware D; Caton JR; Demarco LC; O'Rourke MA; Shaw Wright G; Boehm KA; Asmar L; Bromund J; Peng G; Monberg MJ; Bepler G
    J Clin Oncol; 2009 Dec; 27(34):5808-15. PubMed ID: 19884554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of RRM1 and ERCC1 genes in tumor tissues and peripheral blood lymphocytes of advanced non-small cell lung cancer].
    Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Shen-Tu JZ
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):540-6. PubMed ID: 23086647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomics and gemcitabine.
    Rosell R; Cobo M; Isla D; Camps C; Massuti B
    Ann Oncol; 2006 May; 17 Suppl 5():v13-16. PubMed ID: 16807441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
    Bellmunt J; Paz-Ares L; Cuello M; Cecere FL; Albiol S; Guillem V; Gallardo E; Carles J; Mendez P; de la Cruz JJ; Taron M; Rosell R; Baselga J;
    Ann Oncol; 2007 Mar; 18(3):522-8. PubMed ID: 17229776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients].
    Ma K; Li E; Guo Y; Wang X; Sun H; Shao G
    Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):505-10. PubMed ID: 25327655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.
    Ryu JS; Shin ES; Nam HS; Yi HG; Cho JH; Kim CS; Kim HJ; Lee JE
    J Thorac Oncol; 2011 Aug; 6(8):1320-9. PubMed ID: 21642870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy.
    Wu GQ; Liu NN; Xue XL; Cai LT; Zhang C; Qu QR; Yan XJ
    Asian Pac J Cancer Prev; 2014; 15(10):4153-8. PubMed ID: 24935362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
    Souglakos J; Boukovinas I; Taron M; Mendez P; Mavroudis D; Tripaki M; Hatzidaki D; Koutsopoulos A; Stathopoulos E; Georgoulias V; Rosell R
    Br J Cancer; 2008 May; 98(10):1710-5. PubMed ID: 18414411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.